 Proto-Oncogene Proteins c-bcl-2
"Proto-Oncogene Proteins c-bcl-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Membrane proteins encoded by the BCL-2 GENES and serving as potent inhibitors of cell death by APOPTOSIS. The proteins are found on mitochondrial, microsomal, and NUCLEAR MEMBRANE sites within many cell types. Overexpression of bcl-2 proteins, due to a translocation of the gene, is associated with follicular lymphoma.
| Descriptor ID |
D019253
|
| MeSH Number(s) |
D12.644.360.075.718 D12.776.476.075.718 D12.776.624.664.700.169
|
| Concept/Terms |
Proto-Oncogene Proteins c-bcl-2- Proto-Oncogene Proteins c-bcl-2
- Proto Oncogene Proteins c bcl 2
- c-bcl-2, Proto-Oncogene Proteins
- bcl-2 Proto-Oncogene Proteins
- Proto-Oncogene Proteins, bcl-2
- bcl 2 Proto Oncogene Proteins
- c-bcl-2 Proteins
- c bcl 2 Proteins
B-Cell Leukemia 2 Family Proteins- B-Cell Leukemia 2 Family Proteins
- B Cell Leukemia 2 Family Proteins
- BCL2 Family Proteins
- Family Proteins, BCL2
- Proteins, BCL2 Family
- BCL2 Proteins
- Proteins, BCL2
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-bcl-2".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-bcl-2".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-bcl-2" by people in this website by year, and whether "Proto-Oncogene Proteins c-bcl-2" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 | | 1997 | 2 | 3 | 5 | | 1999 | 1 | 3 | 4 | | 2000 | 2 | 1 | 3 | | 2001 | 3 | 2 | 5 | | 2002 | 5 | 5 | 10 | | 2003 | 4 | 5 | 9 | | 2004 | 4 | 4 | 8 | | 2005 | 1 | 5 | 6 | | 2006 | 1 | 7 | 8 | | 2007 | 4 | 5 | 9 | | 2008 | 2 | 5 | 7 | | 2009 | 3 | 4 | 7 | | 2010 | 2 | 2 | 4 | | 2011 | 2 | 2 | 4 | | 2012 | 7 | 1 | 8 | | 2013 | 3 | 4 | 7 | | 2014 | 3 | 4 | 7 | | 2015 | 1 | 3 | 4 | | 2016 | 2 | 3 | 5 | | 2017 | 1 | 3 | 4 | | 2018 | 2 | 4 | 6 | | 2019 | 3 | 1 | 4 | | 2020 | 0 | 1 | 1 | | 2021 | 1 | 2 | 3 | | 2022 | 0 | 5 | 5 | | 2023 | 0 | 4 | 4 | | 2024 | 1 | 1 | 2 | | 2025 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-bcl-2" by people in Profiles.
-
Singh M, Sarhan MO, Damiba NNL, Singh AK, Villabona-Rueda A, Nino-Meza OJ, Chen X, Masias-Leon Y, Ruiz-Gonzalez CE, Ordonez AA, D'Alessio FR, Aboagye EO, Carroll LS, Jain SK. Proapoptotic Bcl-2 inhibitor as potential host directed therapy for pulmonary tuberculosis. Nat Commun. 2025 Mar 27; 16(1):3003.
-
Bricelj A, Dora Ng YL, Gobec M, Kuchta R, Hu W, Javornik ?, Ro?ic M, G?tschow M, Zheng G, Kr?nke J, Steinebach C, Sosic I. Design, Synthesis, and Evaluation of BCL-2 Targeting PROTACs. Chemistry. 2024 Aug 12; 30(45):e202400430.
-
Cooley JC, Redente EF. Getting the Timing Right: Controlling BCL-2 Inhibition as an Antifibrotic Therapy. Am J Respir Cell Mol Biol. 2024 Apr; 70(4):231-232.
-
Zayac AS, Landsburg DJ, Hughes ME, Bock AM, Nowakowski GS, Ayers EC, Girton M, Hu M, Beckman AK, Li S, Medeiros LJ, Chang JE, Stepanovic A, Kurt H, Sandoval-Sus J, Ansari-Lari MA, Kothari SK, Kress A, Xu ML, Torka P, Sundaram S, Smith SD, Naresh KN, Karimi YH, Epperla N, Bond DA, Farooq U, Saad M, Evens AM, Pandya K, Naik SG, Kamdar M, Haverkos B, Karmali R, Oh TS, Vose JM, Nutsch H, Rubinstein PG, Chaudhry A, Olszewski AJ. High-grade B-cell lymphoma, not otherwise specified: a?multi-institutional retrospective study. Blood Adv. 2023 11 14; 7(21):6381-6394.
-
Cooley JC, Javkhlan N, Wilson JA, Foster DG, Edelman BL, Ortiz LA, Schwartz DA, Riches DW, Redente EF. Inhibition of antiapoptotic BCL-2 proteins with ABT-263 induces fibroblast apoptosis, reversing persistent pulmonary fibrosis. JCI Insight. 2023 02 08; 8(3).
-
Nasr Z, Schoeps VA, Ziaei A, Virupakshaiah A, Adams C, Casper TC, Waltz M, Rose J, Rodriguez M, Tillema JM, Chitnis T, Graves JS, Benson L, Rensel M, Krupp L, Waldman AT, Weinstock-Guttman B, Lotze T, Greenberg B, Aaen G, Mar S, Schreiner T, Hart J, Simpson-Yap S, Mesaros C, Barcellos LF, Waubant E. Gene-environment interactions increase the risk of paediatric-onset multiple sclerosis associated with household chemical exposures. J Neurol Neurosurg Psychiatry. 2023 07; 94(7):518-525.
-
Sak M, Williams BJ, Zumbar CT, Teer L, Al-Kawaaz MNG, Kakar A, Hey AJ, Wilson MJ, Schier LM, Chen J, Lehman NL. The CNS-penetrating taxane drug TPI 287 potentiates antiglioma activity of the AURKA inhibitor alisertib in vivo. Cancer Chemother Pharmacol. 2023 02; 91(2):191-201.
-
Cheung LC, Aya-Bonilla C, Cruickshank MN, Chiu SK, Kuek V, Anderson D, Chua GA, Singh S, Oommen J, Ferrari E, Hughes AM, Ford J, Kunold E, Hesselman MC, Post F, Faulk KE, Breese EH, Guest EM, Brown PA, Loh ML, Lock RB, Kees UR, Jafari R, Malinge S, Kotecha RS. Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy. Leukemia. 2023 01; 37(1):61-71.
-
Singh V, Rana NK, Kashif M, Manna PP, Basu Baul TS, Koch B. Aqua-(2-formylbenzoato)triphenyltin(IV) induces cell cycle arrest and apoptosis in hypoxic triple negative breast cancer cells. Toxicol In Vitro. 2023 Feb; 86:105484.
-
Hu G, Hauk PJ, Zhang N, Elsegeiny W, Guardia CM, Kullas A, Crosby K, Deterding RR, Schedel M, Reynolds P, Abbott JK, Knight V, Pittaluga S, Raffeld M, Rosenzweig SD, Bonifacino JS, Uzel G, Williamson PR, Gelfand EW. Autophagy-associated immune dysregulation and hyperplasia in a patient with compound heterozygous mutations in ATG9A. Autophagy. 2023 02; 19(2):678-691.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|